Does the media refer more to BMRN or LEGN?

In the previous week, BioMarin Pharmaceutical had 29 more articles in the media than Legend Biotech. MarketBeat recorded 34 mentions for BioMarin Pharmaceutical and 5 mentions for Legend Biotech. BioMarin Pharmaceutical's average media sentiment score of 0.73 beat Legend Biotech's score of -0.14 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 13 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, LEGN or EXEL?

Exelixis has higher revenue and earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Legend Biotech $1.03B 3.94 -$296.80M -$0.25 N/A Exelixis $2.32B 5.78 $782.57M $3.18 17.01

Is LEGN or EXEL more profitable?

Exelixis has a net margin of 35.33% compared to Legend Biotech's net margin of -7.21%. Exelixis' return on equity of 42.17% beat Legend Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Legend Biotech -7.21% -8.71% -5.40% Exelixis 35.33% 42.17% 31.76%

Does the media favor LEGN or EXEL?

In the previous week, Exelixis had 11 more articles in the media than Legend Biotech. MarketBeat recorded 16 mentions for Exelixis and 5 mentions for Legend Biotech. Exelixis' average media sentiment score of 1.18 beat Legend Biotech's score of -0.14 indicating that Exelixis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Exelixis 11 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ARWR or LEGN?

In the previous week, Arrowhead Pharmaceuticals had 10 more articles in the media than Legend Biotech. MarketBeat recorded 15 mentions for Arrowhead Pharmaceuticals and 5 mentions for Legend Biotech. Arrowhead Pharmaceuticals' average media sentiment score of 0.90 beat Legend Biotech's score of -0.14 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor LEGN or MDGL?

In the previous week, Madrigal Pharmaceuticals had 2 more articles in the media than Legend Biotech. MarketBeat recorded 7 mentions for Madrigal Pharmaceuticals and 5 mentions for Legend Biotech. Madrigal Pharmaceuticals' average media sentiment score of 1.08 beat Legend Biotech's score of -0.14 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Madrigal Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to HALO or LEGN?

In the previous week, Halozyme Therapeutics had 10 more articles in the media than Legend Biotech. MarketBeat recorded 15 mentions for Halozyme Therapeutics and 5 mentions for Legend Biotech. Halozyme Therapeutics' average media sentiment score of 1.04 beat Legend Biotech's score of -0.14 indicating that Halozyme Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Legend Biotech (LEGN) Competitors

$21.82 +0.56 (+2.63%)

As of 08/21/2026 04:00 PM Eastern

Compare

LEGN vs. BMRN, EXEL, ARWR, MDGL, and HALO

Should you buy Legend Biotech stock or one of its competitors? Legend Biotech's main competitors and comparable companies include BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Arrowhead Pharmaceuticals (ARWR), Madrigal Pharmaceuticals (MDGL), and Halozyme Therapeutics (HALO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Legend Biotech compare to BioMarin Pharmaceutical?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Legend Biotech (NASDAQ:LEGN) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

BioMarin Pharmaceutical has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market.

BioMarin Pharmaceutical has higher revenue and earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	4.01	$348.90M	$0.37	180.27
Legend Biotech	$1.03B	3.94	-$296.80M	-$0.25	N/A

BioMarin Pharmaceutical has a net margin of 2.14% compared to Legend Biotech's net margin of -7.21%. BioMarin Pharmaceutical's return on equity of 5.32% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
Legend Biotech	-7.21%	-8.71%	-5.40%

BioMarin Pharmaceutical presently has a consensus price target of $88.83, indicating a potential upside of 33.17%. Legend Biotech has a consensus price target of $52.29, indicating a potential upside of 139.62%. Given Legend Biotech's higher possible upside, analysts plainly believe Legend Biotech is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.75
Legend Biotech	1 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.47

In the previous week, BioMarin Pharmaceutical had 29 more articles in the media than Legend Biotech. MarketBeat recorded 34 mentions for BioMarin Pharmaceutical and 5 mentions for Legend Biotech. BioMarin Pharmaceutical's average media sentiment score of 0.73 beat Legend Biotech's score of -0.14 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	13 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Legend Biotech	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 0.7% of BioMarin Pharmaceutical shares are owned by company insiders. Comparatively, 0.0% of Legend Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

BioMarin Pharmaceutical beats Legend Biotech on 15 of the 17 factors compared between the two stocks.

How does Legend Biotech compare to Exelixis?

Legend Biotech (NASDAQ:LEGN) and Exelixis (NASDAQ:EXEL) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.

Legend Biotech has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market.

Legend Biotech currently has a consensus target price of $52.29, suggesting a potential upside of 139.62%. Exelixis has a consensus target price of $50.07, suggesting a potential downside of 7.42%. Given Legend Biotech's stronger consensus rating and higher possible upside, equities research analysts clearly believe Legend Biotech is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.47
Exelixis	2 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.30

Exelixis has a net margin of 35.33% compared to Legend Biotech's net margin of -7.21%. Exelixis' return on equity of 42.17% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-7.21%	-8.71%	-5.40%
Exelixis	35.33%	42.17%	31.76%

70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by company insiders. Comparatively, 2.6% of Exelixis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Exelixis had 11 more articles in the media than Legend Biotech. MarketBeat recorded 16 mentions for Exelixis and 5 mentions for Legend Biotech. Exelixis' average media sentiment score of 1.18 beat Legend Biotech's score of -0.14 indicating that Exelixis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Exelixis	11 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis has higher revenue and earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	3.94	-$296.80M	-$0.25	N/A
Exelixis	$2.32B	5.78	$782.57M	$3.18	17.01

Summary

Exelixis beats Legend Biotech on 14 of the 17 factors compared between the two stocks.

How does Legend Biotech compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Legend Biotech (NASDAQ:LEGN) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Legend Biotech has a net margin of -7.21% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Legend Biotech's return on equity of -8.71% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%
Legend Biotech	-7.21%	-8.71%	-5.40%

In the previous week, Arrowhead Pharmaceuticals had 10 more articles in the media than Legend Biotech. MarketBeat recorded 15 mentions for Arrowhead Pharmaceuticals and 5 mentions for Legend Biotech. Arrowhead Pharmaceuticals' average media sentiment score of 0.90 beat Legend Biotech's score of -0.14 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Legend Biotech	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arrowhead Pharmaceuticals currently has a consensus target price of $97.33, suggesting a potential upside of 11.74%. Legend Biotech has a consensus target price of $52.29, suggesting a potential upside of 139.62%. Given Legend Biotech's higher probable upside, analysts clearly believe Legend Biotech is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Legend Biotech	1 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.47

Arrowhead Pharmaceuticals has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	14.79	-$1.63M	-$2.25	N/A
Legend Biotech	$1.03B	3.94	-$296.80M	-$0.25	N/A

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Arrowhead Pharmaceuticals has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

Summary

Arrowhead Pharmaceuticals beats Legend Biotech on 9 of the 16 factors compared between the two stocks.

How does Legend Biotech compare to Madrigal Pharmaceuticals?

Legend Biotech (NASDAQ:LEGN) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

Legend Biotech has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -1.01, indicating that its share price is 201% less volatile than the broader market.

Legend Biotech has a net margin of -7.21% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Legend Biotech's return on equity of -8.71% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-7.21%	-8.71%	-5.40%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

In the previous week, Madrigal Pharmaceuticals had 2 more articles in the media than Legend Biotech. MarketBeat recorded 7 mentions for Madrigal Pharmaceuticals and 5 mentions for Legend Biotech. Madrigal Pharmaceuticals' average media sentiment score of 1.08 beat Legend Biotech's score of -0.14 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Madrigal Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Madrigal Pharmaceuticals has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Madrigal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	3.94	-$296.80M	-$0.25	N/A
Madrigal Pharmaceuticals	$958.40M	12.45	-$288.28M	-$12.89	N/A

Legend Biotech currently has a consensus price target of $52.29, indicating a potential upside of 139.62%. Madrigal Pharmaceuticals has a consensus price target of $689.93, indicating a potential upside of 33.52%. Given Legend Biotech's higher probable upside, analysts plainly believe Legend Biotech is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.47
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 0.0% of Legend Biotech shares are held by insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Madrigal Pharmaceuticals beats Legend Biotech on 9 of the 16 factors compared between the two stocks.

How does Legend Biotech compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and Legend Biotech (NASDAQ:LEGN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

97.8% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by company insiders. Comparatively, 0.0% of Legend Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Halozyme Therapeutics has higher revenue and earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.66B	7.38	$316.89M	$3.35	32.29
Legend Biotech	$1.03B	3.94	-$296.80M	-$0.25	N/A

Halozyme Therapeutics has a net margin of 24.86% compared to Legend Biotech's net margin of -7.21%. Halozyme Therapeutics' return on equity of 260.98% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
Legend Biotech	-7.21%	-8.71%	-5.40%

In the previous week, Halozyme Therapeutics had 10 more articles in the media than Legend Biotech. MarketBeat recorded 15 mentions for Halozyme Therapeutics and 5 mentions for Legend Biotech. Halozyme Therapeutics' average media sentiment score of 1.04 beat Legend Biotech's score of -0.14 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	10 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Legend Biotech	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Halozyme Therapeutics presently has a consensus target price of $91.20, suggesting a potential downside of 15.69%. Legend Biotech has a consensus target price of $52.29, suggesting a potential upside of 139.62%. Given Legend Biotech's higher probable upside, analysts clearly believe Legend Biotech is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Legend Biotech	1 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.47

Halozyme Therapeutics has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market.

Summary

Halozyme Therapeutics beats Legend Biotech on 15 of the 16 factors compared between the two stocks.

Get Legend Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LEGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LEGN vs. The Competition

Export

Metric	Legend Biotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.05B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-87.28	11.62	272.60	24.24
Price / Sales	3.94	1,338.17	618.96	99.78
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	3.30	16.80	13.05	6.20
Net Income	-$296.80M	-$12.50M	$3.47B	$348.59M
7 Day Performance	7.12%	3.29%	2.09%	0.08%
1 Month Performance	-7.27%	8.23%	6.64%	3.88%
1 Year Performance	-38.64%	55.05%	25.02%	16.98%

Legend Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LEGN Legend Biotech	2.834 of 5 stars	$21.82 +2.6%	$52.29 +139.6%	-38.6%	$4.05B	$1.03B	N/A	2,965	Analyst Downgrade Analyst Revision
BMRN BioMarin Pharmaceutical	4.8149 of 5 stars	$66.64 -1.1%	$88.45 +32.7%	+13.9%	$13.04B	$3.22B	180.11	3,221	Analyst Forecast
EXEL Exelixis	3.3853 of 5 stars	$52.32 +2.1%	$49.79 -4.8%	+40.0%	$12.70B	$2.32B	16.45	1,077	News Coverage Positive News Analyst Forecast
ARWR Arrowhead Pharmaceuticals	2.2395 of 5 stars	$88.70 +2.4%	$97.33 +9.7%	+308.4%	$12.20B	$829.45M	N/A	400	News Coverage Insider Trade
MDGL Madrigal Pharmaceuticals	3.8051 of 5 stars	$524.87 +3.4%	$689.93 +31.4%	+24.6%	$11.73B	$958.40M	N/A	90	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LEGN) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Legend Biotech (LEGN) Competitors

LEGN vs. BMRN, EXEL, ARWR, MDGL, and HALO

How does Legend Biotech compare to BioMarin Pharmaceutical?

Summary

How does Legend Biotech compare to Exelixis?

Summary

How does Legend Biotech compare to Arrowhead Pharmaceuticals?

Summary

How does Legend Biotech compare to Madrigal Pharmaceuticals?

Summary

How does Legend Biotech compare to Halozyme Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEGN vs. The Competition

Legend Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Legend Biotech (LEGN) Competitors

LEGN vs. BMRN, EXEL, ARWR, MDGL, and HALO

How does Legend Biotech compare to BioMarin Pharmaceutical?

Which has more volatility & risk, BMRN or LEGN?

Which has preferable valuation and earnings, BMRN or LEGN?

Is BMRN or LEGN more profitable?

Do analysts rate BMRN or LEGN?

Does the media refer more to BMRN or LEGN?

Do institutionals and insiders believe in BMRN or LEGN?

Summary

How does Legend Biotech compare to Exelixis?

Which has more volatility & risk, LEGN or EXEL?

Do analysts prefer LEGN or EXEL?

Is LEGN or EXEL more profitable?

Do institutionals & insiders hold more shares of LEGN or EXEL?

Does the media favor LEGN or EXEL?

Which has higher valuation & earnings, LEGN or EXEL?

Summary

How does Legend Biotech compare to Arrowhead Pharmaceuticals?

Is ARWR or LEGN more profitable?

Does the media refer more to ARWR or LEGN?

Do analysts prefer ARWR or LEGN?

Which has better earnings and valuation, ARWR or LEGN?

Do institutionals and insiders have more ownership in ARWR or LEGN?

Which has more volatility and risk, ARWR or LEGN?

Summary

How does Legend Biotech compare to Madrigal Pharmaceuticals?

Which has more volatility & risk, LEGN or MDGL?

Is LEGN or MDGL more profitable?

Does the media favor LEGN or MDGL?

Which has better earnings and valuation, LEGN or MDGL?

Do analysts prefer LEGN or MDGL?

Do institutionals & insiders believe in LEGN or MDGL?

Summary

How does Legend Biotech compare to Halozyme Therapeutics?

Do institutionals and insiders hold more shares of HALO or LEGN?

Which has preferable earnings & valuation, HALO or LEGN?

Is HALO or LEGN more profitable?

Does the media refer more to HALO or LEGN?

Do analysts recommend HALO or LEGN?

Which has more risk & volatility, HALO or LEGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEGN vs. The Competition

Legend Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools